Given its function as a tumor suppressor, mutations in TP53 predict poor prognosis in acute myelogenous leukemia and chronic lymphocytic leukemia in National Comprehensive Cancer Network guidelines and in multiple myeloma in the Mayo Clinic Stratification for Myeloma and Risk-Adapted Therapy system. Here, TP53 is linked to AL amyloidosis.